Cardiosense is a Chicago-based health-tech company building an AI platform that turns raw physiological signals into clinical intelligence for heart failure. Its FDA-cleared CardioTag wearable simultaneously captures ECG, PPG and seismocardiogram (SCG) signals, and its machine-learning algorithms estimate pulmonary capillary wedge pressure (PCWP) - a key measure of cardiac filling pressure - noninvasively, so clinicians can spot a worsening heart before it lands a patient in the hospital.
Eric Meizlish is the CEO of Cardiosense, a Chicago digital health company building AI-enabled, non-invasive cardiac monitoring. A Yale-trained investor turned healthcare operator, he co-founded the clinical analytics firm Lumere (sold to GHX), ran the life-sciences procurement platform Prendio-BioProcure, and started his career investing in tech and media at Citadel. He took the Cardiosense top job in September 2025 to scale the company's CardioTag sensor, which predicts pressures and volumes inside the heart without an implant.